Jeremie Guedj1, Harel Dahari2, Ralf T Pohl3, Peter Ferenci4, Alan S Perelson5. 1. Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA. 2. Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA; Department of Medicine, University of Illinois at Chicago, IL 60612, USA. 3. Rottapharm Madaus, Madaus GmbH, Colonia Allee 15, Cologne 51067, Germany. 4. Internal Medicine 3, Department of Gastroenterology and Hepatology, Medical University of Vienna, Austria. 5. Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA. Electronic address: asp@lanl.gov.
Abstract
BACKGROUND & AIMS: Legalon® SIL (SIL) is a chemically hydrophilized version of silibinin that has exhibited high antiviral effectiveness against hepatitis C virus (HCV). Its main mode of action (MOA) remains unclear, with contradicting in vitro studies supporting either suppression of entry and cell-to-cell spread or suppression of viral RNA synthesis as the main MOA. We sought to provide new insights into SIL's MOA in HCV genotype-1/4 patients receiving intravenous SIL monotherapy for 7 days via mathematical modeling. METHODS: Changes in HCV RNA in 25 patients receiving 10, 15, or 20mg/kg/day of SIL were analyzed and modeled using viral kinetic methods. RESULTS: In 15 patients, the virus declined in a biphasic manner, in which a sharp drop between days 0 and 2 was followed by a slower second phase of decline. In 10 patients, the initial decline was weaker and the virus declined in a single phase over the 7-day period. The blocking production effectiveness, ε, was dose-dependent with mean ε=0.49 and 0.89 in the 10 or 15 and 20mg/kg/day dosing groups, respectively (p=0.02). The effectiveness of blocking viral infection, η, was estimated as 0.60 with no significant differences across dosing groups. For all patients, the mean rate of viral load decline measured between days 2 and 7 was high (0.3 log(10)IU/ml/day), i.e., 4-fold higher than typically observed during the 2nd phase of (pegylated)-interferon-α±ribavirin treatment. CONCLUSIONS: Modeling HCV kinetics in vivo suggests that SIL may block both viral infection and viral production/release with its main dose-dependent effect being blocking viral production/release. Copyright Â
BACKGROUND & AIMS: Legalon® SIL (SIL) is a chemically hydrophilized version of silibinin that has exhibited high antiviral effectiveness against hepatitis C virus (HCV). Its main mode of action (MOA) remains unclear, with contradicting in vitro studies supporting either suppression of entry and cell-to-cell spread or suppression of viral RNA synthesis as the main MOA. We sought to provide new insights into SIL's MOA in HCV genotype-1/4 patients receiving intravenous SIL monotherapy for 7 days via mathematical modeling. METHODS: Changes in HCV RNA in 25 patients receiving 10, 15, or 20mg/kg/day of SIL were analyzed and modeled using viral kinetic methods. RESULTS: In 15 patients, the virus declined in a biphasic manner, in which a sharp drop between days 0 and 2 was followed by a slower second phase of decline. In 10 patients, the initial decline was weaker and the virus declined in a single phase over the 7-day period. The blocking production effectiveness, ε, was dose-dependent with mean ε=0.49 and 0.89 in the 10 or 15 and 20mg/kg/day dosing groups, respectively (p=0.02). The effectiveness of blocking viral infection, η, was estimated as 0.60 with no significant differences across dosing groups. For all patients, the mean rate of viral load decline measured between days 2 and 7 was high (0.3 log(10)IU/ml/day), i.e., 4-fold higher than typically observed during the 2nd phase of (pegylated)-interferon-α±ribavirin treatment. CONCLUSIONS: Modeling HCV kinetics in vivo suggests that SIL may block both viral infection and viral production/release with its main dose-dependent effect being blocking viral production/release. Copyright Â
Authors: M Lindh; B Arnholm; A Eilard; M Färkkilä; K Hellstrand; M Lagging; N Langeland; K Mørch; S Nilsson; C Pedersen; M R Buhl; T Wahlberg; R Wejstål; J Westin; G Norkrans Journal: J Viral Hepat Date: 2011-06 Impact factor: 3.728
Authors: Andrew H Talal; Ruy M Ribeiro; Kimberly A Powers; Michael Grace; Constance Cullen; Musaddeq Hussain; Marianthi Markatou; Alan S Perelson Journal: Hepatology Date: 2006-05 Impact factor: 17.425
Authors: B A Payer; T Reiberger; K Rutter; S Beinhardt; A F Staettermayer; M Peck-Radosavljevic; P Ferenci Journal: J Clin Virol Date: 2010-08-14 Impact factor: 3.168
Authors: John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir Journal: N Engl J Med Date: 2009-04-30 Impact factor: 91.245
Authors: Jessica Wagoner; Amina Negash; Olivia J Kane; Laura E Martinez; Yaakov Nahmias; Nigel Bourne; David M Owen; Joe Grove; Claire Brimacombe; Jane A McKeating; Eve-Isabelle Pécheur; Tyler N Graf; Nicholas H Oberlies; Volker Lohmann; Feng Cao; John E Tavis; Stephen J Polyak Journal: Hepatology Date: 2010-06 Impact factor: 17.425
Authors: S DebRoy; N Hiraga; M Imamura; C N Hayes; S Akamatsu; L Canini; A S Perelson; R T Pohl; S Persiani; S L Uprichard; C Tateno; H Dahari; K Chayama Journal: J Viral Hepat Date: 2016-06-08 Impact factor: 3.728
Authors: Stephen J Polyak; Nicholas H Oberlies; Eve-Isabelle Pécheur; Harel Dahari; Peter Ferenci; Jean-Michel Pawlotsky Journal: Antivir Ther Date: 2012-09-25
Authors: Laetitia Canini; Anushree Chatterjee; Jeremie Guedj; Annabelle Lemenuel-Diot; Barbara Brennan; Patrick F Smith; Alan S Perelson Journal: Antivir Ther Date: 2014-10-16